Janssen's Darunavir-Based Single-Tablet Effective In Late-Stage Switching Study
Executive Summary
Switching to a once-daily single tablet containing four constituents that is centered on Janssen's protease inhibitor darunavir was non-inferior to other combination therapies after 48 weeks of therapy, say researchers running the Phase III EMERALD study.
You may also be interested in...
J&J’s Symtuza Approved, But Commercial Outlook Uncertain
The first HIV single-tablet regimen anchored by a protease inhibitor, Symtuza’s prospects are challenged by competitors already on the market and treatment guidelines that prefer integrase inhibitor regimens.
AMBER Data Support Green Light For Janssen's Symtuza
More Phase III data for Janssen's first once-daily single tablet containing four drugs for use against HIV Symtuza support its use in treatment-naïve patients; the product awaits US approval.
With J&J’s Departure From HCV, Gilead Stands Alone In ‘Nuc’ Field
J&J is the latest firm to back away from the hepatitis C field, reflecting the dominant position Gilead has built with its sofosbuvir franchise. In February, Merck lowered sales expectations for its investigational "nuc" MK-3682.